DNA RNA and Cells
21 November 2022
Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer21 November 2022
Medera receives FDA clearance for a first-in-human gene therapy trial for heart failure with preserved ejection fraction18 November 2022
Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study17 November 2022
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial14 November 2022
PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates12 November 2022
Kyverna Therapeutics Announces FDA Clearance of IND for KYV-101, a Novel Fully Human CD19 CAR T-Cell Therapy to Treat Lupus Nephritis12 November 2022
Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology’s Kidney Week 202212 November 2022
Carisma Therapeutics Announces Clinical & Pre-Clinical Updates12 November 2022
Triumvira Immunologics Announces Updated Data from Ongoing TACTIC 2 Trial of TAC01-HER2 in Patients with HER2 Positive Solid Tumors12 November 2022
Nutcracker Therapeutics Reports Strong Anti-Tumor Responses of Lead mRNA Immunotherapy in Preclinical Data Presented at SITC Annual Meeting 202211 November 2022
Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates11 November 2022
CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV810210 November 2022
Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting10 November 2022
IconOVir Announces New Preclinical Data Showcasing Best-in-Class Potential of ICVB-1042, its Lead Oncolytic Virus, at SITC 202210 November 2022
Catamaran Bio Presents Preclinical Efficacy Data for Two Allogeneic CAR-NK Cell Therapies for Solid Tumors at SITC 2022 Annual Meeting10 November 2022
CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting7 November 2022
GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ CancersNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports